News | Prostate Cancer | January 18, 2017

PI-RADS Named Best Clinical Research Paper by European Urology

Prostate Imaging Reporting and Data System provides standardized reporting scheme

prostate cancer, PI-RADS, best clinical research paper, European Urology

January 18, 2017 — An article promoting standardized imaging efforts to improve diagnosis and treatment of prostate cancer has been selected as the best clinical research paper published in European Urology

“PI-RADS Prostate Imaging — Reporting and Data System: 2015, Version 2,” written by members of the MR Prostate Imaging Reporting and Data System (PI-RADS) Steering Committee, was published January 2016 in the official journal of the European Association of Urology (EAU). The article provides updated information for the acquisition and standardized interpretation and reporting of multiparametric magnetic resonance imaging (MRI) of the prostate to detect potentially life-threatening cancers.

“Since the publication of this paper last year, the newest version of PI-RADS has been welcomed with open arms and rapidly implemented by the prostate cancer medical community. The positive impact has been tremendous on both clinical care and research concerning the risk of clinically significant prostate cancer that may require biopsy and treatment,” said Jeffrey C. Weinreb, M.D., FACR, co-chair of the MR Prostate Imaging Reporting and Data System (PI-RADS) Steering Committee. Written for medical professionals, the online document along with the European Urology article represent an international scientific consensus, he added. Weinreb noted the steering committee was honored that its efforts received this international distinction. The award will be presented at the EAU annual meeting in March.

The American College of Radiology (ACR) formed a joint effort with AdMeTech Foundation and the European Society of Urogenital Radiology (ESUR) to expedite the transfer of high-quality MRI from laboratories to patients to address a major need in prostate cancer care — reducing unnecessary biopsies and treatment.

Members of the steering committee and authors of the journal article include Weinreb; Jelle O. Barentsz, M.D., Ph.D. (co-chair); Peter L. Choyke, M.D., FACR; François Cornud, M.D.; Masoom A. Haider, M.D.; Katarzyna J. Macura, M.D., Ph.D., FACR; Daniel Margolis, M.D.; Mitchell D. Schnall, M.D., Ph.D., FACR; Clare M. Tempany, M.D.; Harriet C. Thoeny, M.D.; and Sadhna Verma, M.D.

For more information: www.europeanurology.com

References

Weinreb, J.C., Barentsz, J.O., Choyke, P.L., Cornud, F., et al. "PI-RADS Prostate Imaging - Reporting and Data System: 2015, Version 2," European Urology. Published Jan. 1, 2016. DOI: 10.1016/j.eururo.2015.08.052

Related Content

For men with early-stage prostate cancer, choices about initial treatment carry varying risks of "financial toxicity," reports a study in The Journal of Urology, Official Journal of the American Urological Association (AUA). The journal is published in the Lippincott portfolio by Wolters Kluwer.

Getty Images

News | Prostate Cancer | December 02, 2020
December 2, 2020 — ...
During active surveillance, prostate cancer is carefully monitored for signs of progression through regular prostate-specific antigen (PSA) screening, prostate exams, imaging, and repeat biopsies.

Getty Images

News | Prostate Cancer | November 18, 2020
November 18, 2020 — ...
Penn study supports the use of more testicular shielding for men and children during diagnostics

Getty Images

News | Radiology Imaging | November 16, 2020
November 16, 2020 — Early and repeated exposures to diagnostic imaging, such as X-rays and...
Minimizing delays to treatment could improve cancer survival rates, say researchers

Getty Images

News | Radiation Oncology | November 10, 2020
November 10, 2020 — People whose treatment for cancer is delayed by even one month have in many cases a 6 to 13% high
In this retrospective cohort study of men with low-risk prostate cancer followed up for a median of 7.6 years, African American men, compared with non-Hispanic White men, had a statistically significant increased 10-year cumulative incidence of disease progression and definitive treatment, but not metastasis or prostate cancer–specific mortality

Getty Images

News | Prostate Cancer | November 04, 2020
November 4, 2020 — Previous studies have shown that African American men are 2.4 times as likely to die from...
Metastasis-free survival is a strong surrogate endpoint for overall survival over biochemical failure for men receiving salvage radiotherapy for recurrent prostate cancer

Getty Images

News | Prostate Cancer | November 02, 2020
November 2, 2020 — An analysis of the...
Conceptual diagram of bio-organizational crushing technology based on high-intensity concentric ultrasonography. Image courtesy of Korea Institue of Science and Technology(KIST)

Conceptual diagram of bio-organizational crushing technology based on high-intensity concentric ultrasonography. Image courtesy of Korea Institue of Science and Technology(KIST)

News | Ultrasound Imaging | November 02, 2020
November 2, 2020 — Focusing ultrasound energy on a target site in the body to generate heat can burn and destroy the
"Initial report of a randomized trial comparing conventional- vs conventional plus fluciclovine (18F) PET/CT imaging-guided post-prostatectomy radiotherapy for prostate cancer" was presented by Ashesh Jani, M.D., Winship Cancer Institute of Emory University, at ASTRO20
News | PET Imaging | October 26, 2020
October 26, 2020 — Adding the advanced PET radiotracer...